Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NeoLumina Bioscience
Schlieren, Zurich, Switzerlandneolumina.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeoLumina Bioscience is a Swiss clinical-stage biopharmaceutical company dedicated to developing next-generation psychedelic-inspired therapies for mental health conditions. The company's lead program, NLS-1, is a proprietary formulation of psilocybin currently being evaluated in Phase 2 clinical trials for the treatment of anorexia nervosa. NeoLumina aims to address significant unmet needs in psychiatry by refining the delivery and therapeutic profile of psychedelic compounds to treat complex eating disorders. By focusing on rigorous clinical validation and optimized patient outcomes, the company seeks to integrate these novel treatments into mainstream medical practice for underserved psychiatric populations.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on NeoLumina Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoLumina Bioscience.